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Liver fibrosis is the result of a deregulated wound healing process characterized by
the excessive deposition of extracellular matrix. Hepatic stellate cells (HSCs), which are
activated in response to liver injury, are the major source of extracellular matrix and
drive the wound healing process. However, chronic liver damage leads to perpetual
HSC activation, progressive formation of pathological scar tissue and ultimately, cirrhosis
and organ failure. HSC activation is triggered largely in response to mechanosignaling
from the microenvironment, which induces a profibrotic nuclear transcription program
that promotes HSC proliferation and extracellular matrix secretion thereby setting up
a positive feedback loop leading to matrix stiffening and self-sustained, pathological,
HSC activation. Despite the significant progress in our understanding of liver fibrosis, the
molecular mechanisms through which the extracellular matrix promotes HSC activation
are not well understood and no effective therapies have been approved to date that
can target this early, reversible, stage in liver fibrosis. Several new lines of investigation
now provide important insight into this area of study and identify two nuclear targets
whose inhibition has the potential of reversing liver fibrosis by interfering with HSC
activation: Yes-associated protein (YAP), a transcriptional co-activator and effector of the
mechanosensitive Hippo pathway, and bromodomain-containing protein 4 (BRD4), an
epigenetic regulator of gene expression. YAP and BRD4 activity is induced in response to
mechanical stimulation of HSCs and each protein independently controls waves of early
gene expression necessary for HSC activation. Significantly, inhibition of either protein
can revert the chronic activation of HSCs and impede pathological progression of liver
fibrosis in clinically relevant model systems. In this review we will discuss the roles of
these nuclear co-activators in HSC activation, their mechanism of action in the fibrotic
process in the liver and other organs, and the potential of targeting their activity with small
molecule drugs for fibrosis reversal.
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INTRODUCTION
Chronic fibroproliferative disease is a major cause of death in the
industrialized world, placing a substantial burden on healthcare
systems (Mehal et al., 2011; Rockey et al., 2015). In the liver,
chronic injury from a variety of etiologies, including hepatitis,
obesity/metabolic syndrome, and inflammation, leads to liver
fibrosis (Ballestri et al., 2016). While fibrosis due to hepatitis
can be treated with antiviral therapies, nonviral sources remain
difficult to treat (Poordad et al., 2014; Zeuzem et al., 2014)
and once progressed, treatment is limited to slowing escalation
of the disease, but cannot reverse liver fibrosis (Friedman
et al., 2013). The only treatment option for end-stage liver
disease to date is liver transplantation; but this is limited by
availability of donor organs and associated with significant long-
term complications and costs. While the late stages of liver
fibrosis are irreversible, mounting evidence from relevant rodent
models and some patient studies suggest that the early stages
of fibrosis and, potentially, even cirrhosis are reversible (Liu
et al., 2013). Thus, there is an urgent need for the development
of more effective therapeutic strategies that aim to target liver
fibrosis and better knowledge of the molecular events underlying
the early stages of fibrosis holds the key to blocking disease
progression.
Regardless of tissue type and etiology, fibrosis is the result
of an aberrant wound healing response to tissue injury or
inflammation, characterized by excessive remodeling of the
extracellular matrix and progressive scarring (Mehal et al.,
2011; Rockey et al., 2015). This wound healing response is
largely driven by mechanotransduction—that is, intracellular
signaling that is initiated by and mediated through mechanical
forces generated by physical interactions between cells and
the extracellular microenvironment. During the chronic fibrotic
response, mechanical signaling initiated by extracellular matrix
proteins, such as interstitial collagens, leads to a positive
feedback loop by which fibrotic cells produce an excess of
extracellular matrix proteins. This, in turn, leads to increased
tissue stiffness and further activation of fibrotic cells. In the liver,
this process is mainly mediated by HSCs that become activated
and differentiate into myofibroblasts that are proliferative and
fibrogenic (Iwaisako et al., 2014). The switch from quiescent HSC
to myofibroblast involves mechanotransduction-induced gene
transcription of fibrillary collagens and alpha smooth muscle
actin (α-SMA), leading to stress fiber formation, extracellular
matrix deposition and increased cell-extracellular matrix contact.
Ultimately, the resulting tissue contraction promotes chronic
HSC activation through a positive feedback loop involving the
microenvironment and HSCs that perpetuates HSC activation
(Hinz et al., 2007; Friedman, 2008; Butcher et al., 2009;
Mederacke et al., 2013). Importantly, while fibrogenic signaling
is activated during the earliest disease stages, extracellular matrix
accumulation leading to fibrotic scar development only occurs
during the course of chronic tissue injury. Uncovering the
molecular mechanisms that drive early steps in HSC activation
and sustain the deposition of extracellular matrix therefore is key
to halting the mechanosensitive feedback loop and reversing the
fibrotic response.
Recent studies suggest that the gene transcription program
necessary for HSC activation is controlled, at least in part, by
two transcriptional regulators: Yes-associated protein (YAP) and
bromodomain-containing protein 4 (BRD4) (Ding et al., 2015;
Mannaerts et al., 2015). Although these transcriptional regulators
appear to function independently of each other through unique
molecular mechanisms during stellate cell activation, each
is regulated by the microenvironment during liver fibrosis.
Importantly, pharmacologic inhibition of YAP or BRD4 with
small molecules that disrupt their respective interactions with
cofactors has produced promising antifibrotic responses in
murine liver fibrosis models (Ding et al., 2015; Mannaerts et al.,
2015) and thus, represents an attractive therapeutic approach to
treat liver fibrosis in patients. In this review, we will discuss the
roles of these transcription factors in fibroproliferative diseases,
their potential contribution tomechanotransduction duringHSC
activation, and the potential of targeting these proteins that
mediate extracellular matrix stiffness-induced gene expression to
treat patients with fibrosis.
HEPATOCELLULAR STELLATE CELLS
MEDIATE LIVER FIBROSIS
Liver fibrosis is mediated by myofibroblasts that in mice arise
from two cell types: HSCs are the major source of myofibroblasts
in hepatocellular injury (carbon tetrachloride; CCl4) induced
fibrosis, whereas portal fibroblasts are the major source of
myofibroblasts in response to cholestatic injury (bile duct
ligation) induced fibrosis (Iwaisako et al., 2014). Interestingly,
HSCs become activated by portal fibroblasts with longer
durations (14–20 days) of bile duct ligation-induced cholestatic
liver injury, thereafter promoting chronic fibrosis. These
cholestatic injury-induced HSCs are “portal fibroblast-like,”
possessing a gene expression profile—including Thy1 and
elastin—similar to portal fibroblast-derived myofibroblasts
and distinct from that of hepatocellular injury-induced
myofibroblasts, which are characterized by Vitamin A and glial
fibrillary acidic protein (GFAP) expression (Mederacke et al.,
2013; Iwaisako et al., 2014). Thus, HSC activation ultimately
represents the major source of chronic liver fibrosis in both
hepatocellular and cholestatic models.
In healthy livers, quiescent, vitamin A-rich HSCs reside in
the space of Disse (Iwaisako et al., 2014). In response to liver
injury (Figure 1), HSCs proliferate and deposit extracellular
matrix components such as interstitial collagens and matrix
metalloproteinases (MMPs) (Friedman, 2008; Mederacke et al.,
2013). HSCs are thereby ultimately converted into proliferative,
fibrogenic myofibroblasts that express α-SMA (Hinz et al.,
2007; Friedman, 2008). HSC-derived myofibroblasts upregulate
matrix deposition, including fibrillary types I, III, and IV
collagen that are characteristic of all fibrotic diseases and
are each increased up to 10-fold in advanced liver fibrosis
(Westergren-Thorsson et al., 1993; Lucey et al., 1998; Schuppan
et al., 2001; Gressner and Weiskirchen, 2006; Hinz et al.,
2007; Kisseleva and Brenner, 2008). Upon liver damage, HSC-
derived myofibroblasts proliferate and migrate to the site of
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FIGURE 1 | Hepatic stellate cell activation in liver fibrosis. A schematic model of HSC activation in fibrosis is shown. Hepatocellular injuries or inflammation lead
to activation of quiescent, vitamin A-rich, HSCs via signaling processes that involve cytokines, such as TNF-α, TGF-β1 and PDGF. HSC activation leads to
upregulation of gene expression of genes encoding pro-proliferative, cytoskeletal and extracellular matrix components, such as Acta2 (encoding αSMA), Col1A1, FN1
(encoding Fibronectin 1), and Ctgf, leading to subsequent stimulation of HSC proliferation and extracellular matrix secretion. During chronic liver injury, a positive
feedback loop of self-sustained, pathological HSC activation is stimulated where increased HSC proliferation leads to excessive deposition of extracellular matrix. The
resulting increase in matrix stiffness promotes further stress fiber and focal adhesion formation in HSCs by mechanotransduction, leading to increased contractility,
thus perpetuating HSC activation and promoting their transformation into proliferative, fibrogenic myofibroblasts, which are the main mediators of fibrosis. The
persistent population of myofibroblasts, and the resultant crosslinked collagen matrix they produce, causes progressive formation of fibrous scar tissue, ultimately
leading to the destruction of normal tissue architecture and the development of liver fibrosis.
injury to promote wound healing by depositing and remodeling
extracellular matrix components that encapsulate the injury
(Figure 1). During chronic liver injury, however, aberrant wound
healing leads to hyperproliferation and reduced apoptosis of
myofibroblasts. Increased contact between myofibroblasts and
the extracellular matrix is mediated by α-SMA expression-
induced stress fiber and focal adhesion (FA) formation. This
increased contact leads to increased contractility, inducing
mechanotransduction-related signaling (Butcher et al., 2009) and
resulting in excessive extracellular matrix component deposition,
cross-linking of fibrous scar tissue, and increased tissue stiffness
characteristic of human fibroproliferative disease (Figure 1).
Through autocrine and paracrine mechanisms, extracellular
matrix components such as MMPs, fibrillary collagens and
proteoglycans promote growth factor (mainly PDGF) and
cytokine signaling. This signaling, particularly through the
transforming growth factor-beta (TGF-β) and Wnt pathways,
further activates HSCs, thus creating a positive, profibrotic
feedback loop (Figure 1, Karsdal et al., 2015; Li et al., 2015).
Ultimately, mechanotransduction- and growth factor-induced
gene regulation by transcriptional regulators such as YAP and
BRD4 mediate fibroproliferative disease and represents a unique
target for pharmacological intervention for patients with liver
fibrosis.
YAP-INDUCED
MECHANOTRANSDUCTION PROMOTES
LIVER FIBROSIS
YAP and the homologous transcriptional co-activator with PDZ-
binding motif (TAZ) are the ultimate effectors of the Hippo
Frontiers in Pharmacology | www.frontiersin.org 3 December 2016 | Volume 7 | Article 462
Zhubanchaliyev et al. YAP and BRD4 Inhibition Reverses Fibrosis
pathway, a key growth control and tumor suppressor pathway
originally identified by genetic studies inDrosophila melanogaster
(for review see Pan, 2010; Halder and Johnson, 2011; Yu et al.,
2015). The Hippo pathway is a kinase cascade in which the
mammalian homologs of Hippo, the Mammalian Sterile 20-like
kinases 1 and 2 (Mst1/2) activate the large tumor suppressor
kinases 1 and 2 (LATS1/2), which in turn phosphorylate
YAP/TAZ, thereby inducing their cytoplasmic sequestration
by 14-3-3 binding and/or leading to ubiquitin-dependent
degradation (Figure 2). In the absence of Hippo pathway
FIGURE 2 | YAP mediated gene expression in liver fibrosis. Simplified scheme showing the regulation of profibrotic gene expression by YAP during liver fibrosis
and attenuation of gene expression by the inhibitor VP. When the Hippo pathway is on, the active Hippo core kinase complex phosphorylates YAP on five serine
residues leading to either the cytoplasmic sequestration of YAP through interaction with 14-3-3 proteins or the degradation of YAP by the proteasome. Inactivation of
the Hippo core kinase complex in response to initial tissue injury or subsequent mechanotransduction abrogates YAP phosphorylation, leading to nuclear
translocation of YAP, complex formation with TEAD transcription factor(s), and upregulation of profibrotic genes, such as Ctgf and Ankrd1. In cells treated with the
FDA-approved drug VP, which blocks the interaction between YAP and TEADs, YAP/TEAD mediated profibrotic gene expression is blocked, thus preventing HSC
activation and inhibiting or reversing the development of fibrosis. The precise mechanism leading to the activation of Hippo pathway activity in response to upstream
signals during liver fibrosis remains to be determined. Potential upstream regulators including cell-cell contact, GPCRs, and integrins are shown.
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signaling activity, YAP and TAZ translocate to the nucleus
where they serve as transcriptional co-activators that binds
predominantly to TEAD family transcription factors (TEAD1-
4) and promote target gene expression (Yu et al., 2015; Pan,
2010; Halder and Johnson, 2011). YAP/TAZ/TEAD regulated
target genes encode proteins involved in cell proliferation and
inhibition of apoptosis (for review see Johnson and Halder,
2014). Thereby, Hippo signaling regulates the balance between
cell proliferation, apoptosis, and differentiation to control stem
cell proliferation, organ size, as well as tissue homeostasis
(Johnson and Halder, 2014). Pathologically, loss of Hippo
signaling activity and hyperactivation of its downstream effectors
YAP and TAZ through mutations or epigenetic regulation lead to
tissue overgrowth and cancer development (Johnson and Halder,
2014).
The Hippo pathway is primarily regulated by mechanical
inputs from the microenvironment (Figure 2), including cell-
cell contact, matrix stiffness and mechanical stress (stretch
or contraction) (for review see Dupont et al., 2011; Meng
et al., 2016). In addition, Hippo pathway activity is modulated
both, positively and negatively, by G-protein coupled receptors
(GPCRs), select cytokine receptors, such as leukemia inhibitory
factor receptor, and crosstalk with specific signaling pathways,
such as the EGF, Wnt, and bone morphogenic protein (BMP)
pathways (Figure 2, Pan, 2010; Halder and Johnson, 2011; Yu
et al., 2015; Meng et al., 2016). Mechanical cues are transmitted
through activation of cell surface receptors, such as E-cadherins,
integrins, and components of the cell polarity complex, as
well as certain GPCRs that act as mechanoreceptors (Dupont
et al., 2011; Meng et al., 2016). These receptors converge on
RhoA and RhoA-dependent regulation of F-actin polymerization
and actin-myosin contractility (Dupont et al., 2011; Meng
et al., 2016). Cytoskeletal reorganization and contraction, in
turn, alter the activity of the cytoplasmic core components
of the Hippo pathway leading to phosphorylation-induced
cytoplasmic retention and degradation of YAP/TAZ (Dupont
et al., 2011; Meng et al., 2016). F-actin architecture is also
directly linked to YAP regulation via the Hippo pathway
component angiomotin (AMOT) and the related AMOTL1
and AMOTL2 (Chan et al., 2011; Zhao et al., 2011). AMOT
family proteins act as adaptors that recruit YAP/TAZ to
various cellular compartments, such as cell-cell junctions and F-
actin fibers, depending on cellular context (Chan et al., 2011;
Dupont et al., 2011; Zhao et al., 2011). Disruption of junction
complexes or depolymerization of F-actin releases YAP/TAZ
from sequestration by AMOT and drives YAP/TAZ to the nucleus
(Chan et al., 2011; Dupont et al., 2011; Zhao et al., 2011). Thus,
Hippo pathway activity transforms mechanical signals from the
environment through cytoskeletal reorganization into changes
in nuclear expression by controlling YAP/TAZ stability and
nucleocytoplasmic shuttling. Accordingly, extracellular matrix
stiffness affects YAP/TAZ activity and localization, with active
YAP/TAZ localizing predominantly in the nucleus in cells grown
on a stiff surface, whereas YAP/TAZ remain inactive in the
cytoplasm in cells grown on a soft surface (Dupont et al., 2011).
In the mammalian liver, Hippo pathway signaling is involved
in development and regeneration as well as pathological
processes, such as cancer and fibrosis. During liver development,
YAP is important for bile duct formation (tubulogenesis),
although the molecular mechanism remains to be elucidated; no
effect has been observed from YAP deletion in the adult liver
to date (Zhang et al., 2010; Nguyen et al., 2015). However, YAP
plays a positive role in the regeneration response following bile
duct ligation. Accordingly, nuclear localization of YAP increases
after bile duct ligation in mice, and knockout of YAP delays
hepatocyte proliferation 5 days post-injury and inhibits biliary
epithelial cell proliferation 15 days post-injury (Bai et al., 2012).
Conversely, YAP hyperactivation through epigenetic regulation
and amplification is common in liver cancer and a wide variety
of other cancers, thereby promoting tumorigenesis through cell
proliferation, survival and maintenance of the tumor stem cell
phenotype (Johnson and Halder, 2014).
YAP is expressed in the hepatocytes of cholestatic livers
in young patients (Anakk et al., 2013) as well as in patients
with primary sclerosing cholangitis and primary biliary cirrhosis
(Bai et al., 2012). Liver diseases often affect the levels
of serum bile acids and a recent study reported a direct
association of elevated bile acid levels with YAP activation
and proliferation of liver progenitor cells, eventually leading
to the development of spontaneous liver tumors (Anakk et al.,
2013). Importantly, YAP activation is also an early event in
HSC activation and fibrosis development. An elegant study
by Mannaerts et al., recently demonstrated that YAP drives
HSC activation during hepatocellular injury (CCl4) induced
fibrosis in mice (Mannaerts et al., 2015). The authors showed
that YAP translocates into the nuclei of HSCs after CCl4
administration, and inhibition of YAP through knockdown
or pharmacological inhibition with verteporfin (VP) prevents
HSC activation in vitro and fibrogenesis in vivo (Mannaerts
et al., 2015). Knockdown studies and pharmacological inhibition
of upstream Hippo pathway components further show that
YAP stability and nuclear localization during HSC activation
is regulated through modulation of Hippo pathway activity
(Figure 2, Mannaerts et al., 2015). The activation of HSC
correlates with a switch in gene expression that involves
upregulation of genes, which participate in matrix remodeling,
actin cytoskeleton, cell proliferation, and immune processes.
Importantly, some of the most strongly upregulated genes,
such as Ankrd1 (cardiac ankyrin repeat protein) and Ctgf
(connective tissue growth factor), are direct targets of YAP
(Figure 2, Mannaerts et al., 2015). Ankrd1 is a mechanosensitive
transcription factor that is the most highly expressed in the
heart and muscle and mediates TGF-β signaling in response
to injury and stress (Kojic et al., 2011), whereas CTGF is a
cysteine-rich extracellular matrix protein that plays a central
role in tissue remodeling and wound repair by regulating the
induction of genes, such as fibronectin, collagens (types I, III, IV,
and VI) and binding to various cell surface receptors, including
αVβ3 and α5β1 integrins (Lau, 2016). Notably, CTGF promotes
HSC activation and proliferation and plays a critical role in
fibrotic disease (Gressner and Gressner, 2008; Jun and Lau, 2011;
Huang and Brigstock, 2012). Significantly, Ankrd1 and Ctgf were
upregulated much earlier than Acta2 (Mannaerts et al., 2015), a
widely used marker of HSC activation, consistent with the idea
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that YAP controls a very early stage in HSC activation. Similar to
CCl4 treatment, YAP protein and mRNA expression is increased
in the livers of mice 5 days after bile duct ligation, and inhibition
of YAP through liver-specific conditional deletion reduced bile
duct and hepatocyte proliferation, and enhanced hepatocyte
necrosis, likely through a Survivin-dependent mechanism (Bai
et al., 2012). Thus, YAP regulates the early stages of both, acute,
injury-induced, and chronic, cholestatic HSC activation.
During the fibrotic response, YAP serves as a
mechanotransduction mediator, integrating signaling responses
to mechanical cues to promote proliferation, survival, and
extracellular matrix deposition (Dupont et al., 2011; Mannaerts
et al., 2015). HSC activation-mediated extracellular matrix
stiffening leads to YAP activation, which, in turn, leads to
additional extracellular matrix deposition and matrix stiffness
ultimately resulting in a feedback loop promoting sustained HSC
activation and proliferation (Figure 2, Mannaerts et al., 2015).
This was shown through correlative studies in mice and, more
directly, using a novel 3D in spheroids system that accurately
mimics HSCs activation in vitro (Mannaerts et al., 2015).
Activation of HSCs by CCl4 administration to mice induced
nuclear translocation of YAP, increased total YAP protein,
and increased picrosirius red (collagen), α-SMA, and ankyrin
repeat domain 1 (ANKRD1) staining; this HSC activation
was reversed by pharmacologic inhibition of YAP (Mannaerts
et al., 2015). Importantly, this process is entirely dependent
on matrix stiffness: in 3D cultured, quiescent HSCs with a soft
matrix, YAP does not translocate to the nucleus after CCl4
administration, but does translocate into the nucleus after CCl4
administration to HSCs spread on tissue culture plastic—that is,
a stiff matrix—leading to HSC activation as measured by Acta2,
Ankrd1, and Ctgf expression (Butcher et al., 2009; Lu et al., 2012;
Mannaerts et al., 2015). Overall, these studies suggest that YAP
activates initial steps of HSC activation, thus inhibition of YAP
could be a new way for the prevention of liver fibrosis or reverse
its progression.
The role of YAP in mechanotransduction during the
fibrotic response extends beyond hepatic tissues. Indeed,
YAP is expressed in fibrotic, but not healthy, lung tissue
(Liu et al., 2015). As in HSCs, when pulmonary fibroblasts
are grown on a stiff matrix in vitro, YAP accumulates in
the nucleus; likewise, knockdown of YAP impedes matrix
deposition, contraction and proliferation independent of TGF-
β signaling. YAP induces plasminogen activator inhibitor-1
(PAI1), promoting cell-matrix adhesion and continued nuclear
accumulation of YAP, thus resulting in a positive feedback loop by
which YAP mechanotransduction leads to chronic fibrogenesis
(Liu et al., 2015). In contrast to the lung, YAP promotes
TGF-β signaling in fibrotic kidneys and, similar to its role
in human embryonic stem cells, regulates TGF-β signaling by
retaining active SMAD2/3 in the nucleus (Varelas et al., 2008,
2010; Beyer et al., 2013). Similarly to both the liver and the
lung, however, YAP promotes renal fibrogenesis by serving as a
mechanotransducer. YAP-regulated TGF-β-induced profibrotic
SMAD2/3 signaling is inhibited by a soft matrix, but enhanced
by a stiff matrix: pharmacologic inhibition of YAP with VP
inhibited TGF-β-induced SMAD2/3 signaling in vitro in rat
kidney fibroblasts as well as the progression of renal fibrosis
in vivo in a murine unilateral ureteral obstruction model (Szeto
et al., 2016). In this study, VP reduced the absolute mRNA
levels of YAP and its cofactor transcriptional coactivator with
PDZ-binding motif (TAZ) in vitro, which is notable because
VP is thought to inhibit YAP through direct binding, thereby
inducing a conformational change that inhibits interactions with
its essential cofactors, TEAD1-4 (Liu-Chittenden et al., 2012).
Collectively, these studies strongly implicate Hippo signaling,
through YAP, as a critical regulator of chronic fibroproliferative
diseases through its mechanotransductive abilities.
TRANSCRIPTIONAL REGULATION BY
BRD4 PROMOTES LIVER FIBROSIS
Another molecule that plays a key role in regulating profibrotic
mechanotransduction at the transcriptional level is the
bromodomain and extra terminal domain (BET) family
member BRD4. BRD4 is a double bromodomain-containing
transcriptional enhancer that binds to acetylated chromatin
during interphase and mitosis, thereby serving as a co-activator
for transcription of MYC, E2F, and nuclear factor-κB (NF-κB)
regulated cytokines to regulate the cell cycle by promoting G2 to
M phase transition (reviewed in Shi and Vakoc, 2014; Wang and
Filippakopoulos, 2015).
During the fibrotic response, BRD4 promotes the expression
of target genes that are involved in matrix remodeling and
proliferation (Figure 3). Of particular note, BRD4 promotes
the expression of Col1A1, which encodes Type I collagen, in
response to exogenous TGF-β, thereby leading to both lung
and liver fibrosis (Friedman, 2008; Mederacke et al., 2013; Tang
et al., 2013; Ding et al., 2015). Other prominently induced
genes encode components of the cytoskeletal apparatus including
Actg2 and Acta2, which encode smooth muscle gamma-actin
and alpha-actin, respectively (Ding et al., 2015). Inhibition of
BRD4 by both siRNA and JQ1 (or the structurally distinct,
but functionally similar, chemical BRD inhibitors I-BET-151
and PFI-1) markedly reduced profibrotic mRNA expression,
particularly that of Col1A1 and Acta2 (Figure 3), inhibited
PDGF-mediated HSC proliferation, and blocked HSC activation
during CCl4-induced liver fibrosis in mice (Ding et al., 2015).
Similarly, pharmacologic inhibition of BRD4 with JQ1 reverses
bleomycin-induced lung fibrosis in mice, including reduced
tissue hydroxyproline and Collagen I staining, indicating that
BRD4 inhibition can reduce tissue stiffness-associated profibrotic
signaling (Tang et al., 2013).
Collagen is known to activate profibrotic responses in a
matrix stiffness-dependent manner, including the formation
of stress fibers by increasing Acta2 (α-SMA) expression and
promoting profibrotic TGF-β signaling by applying force to
collagen-binding integrin receptors leading to downstream
mechanotransduction and crosstalk with SMAD proteins
(Kanta, 2015). Furthermore, inhibiting αvβ1 integrin attenuates
bleomycin-induced lung and CCl4-induced liver fibrosis in
mice by inhibiting the processing of latent to active TGF-β
(Reed et al., 2015). Thus, collagen deposition leading to
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FIGURE 3 | BRD4 mediated gene expression in liver fibrosis. A hypothetical model is shown illustrating the regulation of profibrotic gene expression by the
double bromodomain-containing transcriptional enhancer BRD4 during liver fibrosis in response to mechanotransduction and attenuation of gene expression by the
bromodomain inhibitor JQ1 that prevents the binding of BRD4 to acetylated chromatin. During the fibrotic response, BRD4 binds to acetylated chromatin via its
bromodomains and thereby promotes the expression of genes, including Col1A1, that are involved in HSC activation, proliferation and matrix remodeling. In the
presence of competitive BRD inhibitors, such as JQ1, I-BET (not shown), and PFI-1 (not shown), BRD4 is prevented from binding to acetylated histones, leading to a
block in transcription elongation and inhibition of TGF-β-stimulated profibrotic gene expression, thereby attenuating HSC activation and fibrosis development. The
precise mechanisms leading to activation of BRD4-mediated transcriptional elongation in response to activation of profibrotic signaling pathways remains to be
determined. One potential mechanism involving latent TGF-β activation by integrins is shown.
integrin activation and mechanotransduction represents a
feedback loop promoting pathologic extracellular matrix
deposition and sustained profibrotic responses. Considering
that BRD4 regulates TGF-β-mediated collagen deposition
during the fibrotic response, an attractive mechanistic
hypothesis is that BRD4 exacerbates TGF-β-mediated
fibrosis and tissue stiffness by increasing signaling
through integrin-mediated mechanotransductive pathways,
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leading to pathologic extracellular matrix remodeling,
enhanced tissue stiffness and sustained HSC activation
(Figure 3).
TARGETING MATRIX
STIFFNESS-INDUCED GENE EXPRESSION
TO TREAT LIVER FIBROSIS
While YAP and BRD4 appear to regulate the expression
of distinct target genes and therefore likely represent two
independent pathways with unique molecular mechanisms, each
is regulated by the microenvironment, and each promotes
extracellular matrix stiffness and mechanotransductive signaling
during liver fibrosis by serving as a coactivator for profibrotic
gene transcription. Likewise, each represents a novel target
in the treatment of liver fibrosis that can be inhibited
by targeting protein-protein interactions with co-activators
via small molecules. YAP transcriptional activity can be
inhibited with VP. Originally developed as a photosensitizer
that is used in FDA-approved photocoagulation therapy for
macular degeneration, VP has been found to bind to YAP
and inhibit its interactions with TEAD proteins, which are
necessary for its effects on transcriptional activation (Liu-
Chittenden et al., 2012). VP has been demonstrated to block
YAP-induced liver tumorigenesis and suppress hepatomegaly
caused by hepatocyte and biliary cell proliferation in YAP
transgenic and NF2 knockout mice (Liu-Chittenden et al.,
2012; Nguyen et al., 2015). Furthermore, VP blocks matrix
stiffness-induced HSC activation in vitro as well as CCl4-
induced fibrogenesis in vivo, including a reduction in Col1A1
gene expression (Mannaerts et al., 2015). As YAP is known
to be expressed in human fibrotic liver and lung tissues (Liu
et al., 2015; Mannaerts et al., 2015), whether pharmacologic
inhibition of YAP by VP can provide a therapeutic effect
for patients with fibrosis is an attractive area for further
study.
Similarly to the mechanism by which VP inhibits YAP,
the competitive bromodomain inhibitor JQ1 inhibits binding
between Histone H4 and bomodomains, thereby preventing
BRD4 from acting as a transcriptional co-activator of target
genes (reviewed in Filippakopoulos and Knapp, 2014). JQ1 was
originally developed as an antitumor drug via a small molecule
screen, and has proven effective in treating in vivo models
of acute myeloid leukemia, multiple myeloma and nuclear
protein of the testis (NUT) midline carcinomas (reviewed in
Filippakopoulos and Knapp, 2014; Wang and Filippakopoulos,
2015). In the context of fibrosis, inhibiting BRD4 with JQ1
inhibits both lung and liver fibrosis as well as HSC activation
in murine models, including reducing TGF-β-mediated Col1A1
expression and extracellular matrix remodeling (Tang et al., 2013;
Ding et al., 2015). Thus, JQ1 represents an attractive small
molecule for further study as potential treatment of human
fibroproliferative diseases and the future development of more
specific and stable BRD4 inhibitors (Theodoulou et al., 2016;
Waring et al., 2016) may open new opportunities for anti-fibrotic
therapy.
CONCLUSIONS AND FUTURE
PROSPECTS
The activation of quiescent HSCs and their transition to a
proliferative, contractile myofibroblast phenotype represents
a critical control point between a normal and pathological
tissue repair response. Few regulatory factors have been
identified that regulate this transition in the liver and that
can be targeted for liver fibrosis reversal. Recent progress has
shown that mechanotransduction induced by increased contact
between activated hepatic myofibroblasts due to pathologic
accumulation of extracellular matrix components and increased
focal adhesion formation is orchestrated, in part, by the
transcriptional co-activators YAP and BRD4 in concert with their
respective transcription factors. Traditionally, small molecule
inhibitor development has focused on disrupting ligand-receptor
interactions rather than transcriptional regulation. However,
no therapies have been developed to date that can reverse
liver fibrosis in patients, which has become a major clinical
challenge in the industrialized world. More effective therapies
are therefore critically needed to treat chronic fibroproliferative
diseases. Given that VP and JQ1 have shown efficacy in in vivo
models of liver fibrosis, targeting the fibrotic response at the
transcriptional level presents an attractive avenue for further
research.
BRD4 and YAP both regulate profibrotic gene expression that
plays a central role in HSC activation, tissue remodeling and
liver fibrosis. Nevertheless, these nuclear co-factors appear to
regulate distinct sets of target genes suggesting that BRD4 and
YAP represent independent pathways that are both critically
involved in the regulation of early stages of fibrosis. Thus,
there appear to be multiple positive feedback loops involving
integrins, TGF-β, and other cytokines that contribute to HSC
activation and fibrosis progression by regulating specific nuclear
gene expression programs through YAP and BRD4. The studies
by Mannaerts et al. (2015) and Ding et al. (2015) suggest that
by inhibiting either YAP or BRD4 action, these positive feedback
loops can be broken, leading to attenuation or reversal of fibrosis.
If true, the rational combinations of YAP and BRD4 inhibitors
may provide synergistic effects and offer a more effective way
to reverse fibrosis progression than the single agents and this
should be a further avenue of research. Toward this aim, it
will be important to confirm the roles of YAP and BRD4 in
fibrosis development and reversal using inducible knockout
mouse mutants for YAP and BRD4 and to evaluate in more
detail the anti-fibrotic action and efficacy of VP and JQ1 in
disease relevant animal models. In addition, a more detailed
understanding of the regulation of and interaction between YAP
and BRD4 pathways will be necessary to define the precise
roles of these pathways in HSC activation and fibrosis. While
YAP and BRD4 each appear to control different populations
of target genes, it is likely that the two pathways cooperate
during HSC activation. Indeed, a recent study using the BRD
inhibitor JQ1 revealed a role of BET bromodomain protein(s)
in regulating the activity of the YAP homolog TAZ (Duan et al.,
2016) indicating a possible point of cross-talk between the two
profibrotic pathways.
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Last, but not least, of particular interest will be the elucidation
of the precise mechanisms by which mechanical signals from
the environment are relayed across the membrane to modulate
YAP and BRD4 function in the nucleus. Integrins are the
primary mechanosensors and transducers of tissue stiffness and
several integrins have been identified as key drivers of profibrotic
signaling in various organs. Some of these integrins, in particular
αv subunit integrins, such as αvβ1 and αvβ6, have been shown
to control the activation of latent TGF-β1 complex and targeting
these integrins with small molecule inhibitors can block or
reverse fibrosis progression in mouse models (Henderson and
Sheppard, 2013; Henderson et al., 2013; Reed et al., 2015; Conroy
et al., 2016). Given that BRD4 is critical for TGF-β-dependent
profibrotic gene expression, BRD4 activity may be one of the
downstream targets of integrin and TGF-β action.
Alternatively, integrins can control HSC activation
through bi-directional “outside-in” and “inside-out” signaling
mechanisms leading to changes in actin organization and
actomyosin contractility and subsequent alterations in tissue
remodeling. Indeed, several integrin-associated signaling
proteins, including integrin-linked kinase (ILK, Zhang et al.,
2006; Li et al., 2009; Kavvadas et al., 2010; Shafiei and Rockey,
2012; Radovanac et al., 2013), focal adhesion kinase (FAK, Wong
et al., 2011; Lagares et al., 2012; Kinoshita et al., 2013; Lagares
and Kapoor, 2013; Zhao et al., 2016), and regulators and effectors
of Rho GTPases, such as P-Rex1 (Liang et al., 2016), PAK and
Rho-activated kinase (ROCK, Knipe et al., 2015; Martin et al.,
2016) have been identified as potential targets for anti-fibrotic
therapy in a number of organs. Notably, activation of ILK, which
links F-actin to focal adhesions and is required for integrin-
mediated force generation, sustains nuclear YAP accumulation
in pulmonary arterial vascular smooth muscle cells to promote
cell proliferation in pulmonary arterial hypertension, a disease
characterized by increased deposition of extracellular matrix and
vascular stiffness (Kudryashova et al., 2016). Consistent with this
notion, regulation of Hippo activation by ILK (Serrano et al.,
2013), Src-FAK (Kim and Gumbiner, 2015; Li et al., 2016), and
beta1 integrins (Martin et al., 2016) has been observed in the
context of epithelial-mesenchyme transition, cancer, as well as
tissue homeostasis in the skin (Elbediwy et al., 2016). Although
the physiological relevance of Hippo pathway regulation by
integrins and their effectors needs to be confirmed in the context
of fibrosis there is accumulating evidence supporting such a role.
Indeed, while this review was under consideration, the integrin
α11β1 was reported to promote liver fibrosis by modulating
hepatic stellate cell activation through the Hippo/YAP pathway
(Martin et al., 2016). Interestingly, knockdown of the α11
subunit in HSCs by RNA interference abolished a subset of YAP-
regulated genes during HSC activation and partially reversed
tissue fibrosis in a mouse model of the disease, indicating
that this particular integrin represents one of likely multiple
mechanosensitive upstream regulators of YAP in liver fibrosis
(Martin et al., 2016).
In sum, mechanotransduction in myofibroblasts is clearly
relevant for fibrotic disease and it is increasingly being realized
that components of mechanosensitive signal transduction
pathways are not only drivers of disease progression, but also
promising targets for therapy. While additional work will be
required to address the precise roles of YAP and BRD4 in
fibrosis, overall the current findings suggest that YAP and
BRD4 are key terminal effectors of mechanosensing signal
transduction pathways that initiate and perpetuate fibrosis and
that targeting YAP and BRD4 alone or in combination has
great promise toward treating patients with organ fibrosis and
reducing the burden of fibroproliferative diseases. Amore refined
understanding of the mechanisms underlying myofibroblast
activation across different organ systems and better insight into
the roles and regulation of YAP and BRD4 in this process could
lead to more personalized treatment options that may slow and
perhaps even reverse fibrosis progression in the future.
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